Evidence-based management of ANCA vasculitis.

Research output: Contribution to journalReview article

Standard

Evidence-based management of ANCA vasculitis. / Carruthers, David; Sherlock, Jonathan.

In: Best Practice & Research: Clinical Rheumatology, Vol. 23, No. 3, 01.06.2009, p. 367-78.

Research output: Contribution to journalReview article

Harvard

APA

Vancouver

Author

Bibtex

@article{a4d4171053b74502845e277db30e3712,
title = "Evidence-based management of ANCA vasculitis.",
abstract = "The vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) present to and are managed by a wide spectrum of physicians, reflecting the multi-organ nature of the conditions. Treatment strategies for these primary inflammatory vascular diseases have varied based on the outcomes of different clinical trials and practice reviews. The individual drugs used and their route of administration, dose, and duration of therapy have varied and have been the source of much debate. Advances in our understanding of disease immunopathogenesis, clinical assessment and outcome have formed the basis for several recent good-quality clinical trials. Now, with the results of these large-scale multicentre collaborative studies, there is a firmer evidence base to guide management decisions for individual patients. This evidence base, reviewed here, has led to the publication of treatment guidelines which importantly encompass many of the broader aspects of disease management.",
author = "David Carruthers and Jonathan Sherlock",
year = "2009",
month = jun,
day = "1",
doi = "10.1016/j.berh.2008.12.003",
language = "English",
volume = "23",
pages = "367--78",
journal = "Best Practice & Research: Clinical Rheumatology",
issn = "1521-6942",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Evidence-based management of ANCA vasculitis.

AU - Carruthers, David

AU - Sherlock, Jonathan

PY - 2009/6/1

Y1 - 2009/6/1

N2 - The vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) present to and are managed by a wide spectrum of physicians, reflecting the multi-organ nature of the conditions. Treatment strategies for these primary inflammatory vascular diseases have varied based on the outcomes of different clinical trials and practice reviews. The individual drugs used and their route of administration, dose, and duration of therapy have varied and have been the source of much debate. Advances in our understanding of disease immunopathogenesis, clinical assessment and outcome have formed the basis for several recent good-quality clinical trials. Now, with the results of these large-scale multicentre collaborative studies, there is a firmer evidence base to guide management decisions for individual patients. This evidence base, reviewed here, has led to the publication of treatment guidelines which importantly encompass many of the broader aspects of disease management.

AB - The vasculitides associated with antineutrophil cytoplasmic antibodies (ANCAs) present to and are managed by a wide spectrum of physicians, reflecting the multi-organ nature of the conditions. Treatment strategies for these primary inflammatory vascular diseases have varied based on the outcomes of different clinical trials and practice reviews. The individual drugs used and their route of administration, dose, and duration of therapy have varied and have been the source of much debate. Advances in our understanding of disease immunopathogenesis, clinical assessment and outcome have formed the basis for several recent good-quality clinical trials. Now, with the results of these large-scale multicentre collaborative studies, there is a firmer evidence base to guide management decisions for individual patients. This evidence base, reviewed here, has led to the publication of treatment guidelines which importantly encompass many of the broader aspects of disease management.

U2 - 10.1016/j.berh.2008.12.003

DO - 10.1016/j.berh.2008.12.003

M3 - Review article

C2 - 19508944

VL - 23

SP - 367

EP - 378

JO - Best Practice & Research: Clinical Rheumatology

JF - Best Practice & Research: Clinical Rheumatology

SN - 1521-6942

IS - 3

ER -